EAM
OCUL icon

Exome Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Exome Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
+181,588
New +$1.65M 1.1% 33
2024
Q2 		– Sell
-193,600
Closed -$1.76M – 64
2024
Q1 		$1.76M Buy
+193,600
New +$1.37M 1.51% 28

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Exome Asset Management's OCUL Position: Q2 2026 in Review

Exome Asset Management opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 181,588 shares worth $1.78M. The stake represents 1.1% of the portfolio and ranks #33 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in OCUL as recently as Q1 2024.

Exome Asset Management first reported a position in OCUL in Q1 2024 and has held it in 2 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Exome Asset Management held 181,588 shares of Ocular Therapeutix worth $1.78M as of Q2 2026.
  • Ocular Therapeutix was a new Exome Asset Management position in Q2 2026.
  • Ocular Therapeutix made up 1.1% of Exome Asset Management's portfolio in Q2 2026, its #33 holding.
  • Exome Asset Management first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 2 quarters since.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.